Drug metabolism and personalized therapy最新文献

{"title":"Lauric acid modulates cytochrome 4V2 expression in the human THP1 macrophages.","authors":"Yazun Bashir Jarrar, Wisam Nasser, Su-Jun Lee","doi":"10.1515/dmpt-2025-0008","DOIUrl":"https://doi.org/10.1515/dmpt-2025-0008","url":null,"abstract":"<p><strong>Objectives: </strong>Macrophages play a major role in the inflammation. Recently, the expression of some cytochrome P450 (CYP450) 4 family enzymes was identified in the macrophages including CYP4V2, which metabolizes saturated fatty acids. Lauric acid is unsaturated fatty acid, which can induce inflammation. Its effect on the expression of CYP4V2 and the inflammatory mediators in macrophages is still unknown. This study aims to investigate the effect of lauric acid on the expression of CYP4V2 and cyclo-oxygenase 2 (COX2) in the human monocytes and macrophage THP1 cell line.</p><p><strong>Methods: </strong>The THP1 monocyte cell line was differentiated into macrophages using 100 ng/mL PMA. Then, the cells were treated with 10 µM lauric acid for 72 h. The mRNA and protein expression of human CYP4V2 and COX2 were analyzed using real-time and western blot techniques, respectively.</p><p><strong>Results: </strong>It was found that the mRNA and protein expression of CYP4V2 was upregulated after treatment of the macrophages with lauric acid in a dose-dependent manner. This upregulation was correlated with the expression of COX2.</p><p><strong>Conclusions: </strong>It can be concluded from the results of this study that mRNA and protein expression of CYP4V2 are upregulated by lauric acid in correlation with the induction of inflammation. CYP4V2 can play a role in the inflammation process managed by macrophages.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144149656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunomodulatory potential of phosphorus: insights from experimental mice models under normal and immunosuppressive condition.","authors":"Sangita Behera, Mahima Sharma, Raj Kumar Regar, Pankaj Gupta, Shaheen Jabbar, Godlaveti Vijay Narasimha Kumar, Satvinder Singh","doi":"10.1515/dmpt-2024-0103","DOIUrl":"https://doi.org/10.1515/dmpt-2024-0103","url":null,"abstract":"<p><strong>Objectives: </strong>Phosphorus, an essential mineral with diverse biological functions, has recently garnered attention for its potential role in modulating the immune system. However, no study is present regarding the effect of homoepthic preparation of Phosphorus on immune system. Thus, this study aims to investigate the immunomodulatory effects of Phosphorus, shedding light on its impact on Normal and Immunosuppressive conditions in mice.</p><p><strong>Methods: </strong>The immunomodulatory effect of Phosphorus 6C, 30C, and 200C was tested using Sheep red blood cells on humoral antibody titer and delayed-type hypersensitivity assays. The effect of Phosphorus was investigated in cyclophosphamide induced immune-compromised mice by assessing hematology, organ index, phagocytic index, histology, cytokine level, and their mRNA expression in the spleen.</p><p><strong>Results: </strong>Phosphorus 6C produced a significant increase in the primary and secondary humoral immune response. While Phosphorus treatment at 6C, 30C, and 200C did not significantly alter hematological and organ index parameters, it considerably enhance the phagocytic index at 30C and 200C, and raise the levels of TNF-α and IL-2 in mice against immunosuppression induced by CPM after the pretreatment with Phosphorus-30C.</p><p><strong>Conclusions: </strong>The present study shows that Phosphorus 6C potency augment the humoral immunity. In case of immunosuppression, Phosphorus at high dilution might play a significant role but more research is needed to find out the possible effect of Phosphorus preparation.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143982807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigating the crossroads of cell death interplay and intersections among ferroptosis, apoptosis and autophagy.","authors":"Anuupama Suchiita, Navya Gupta, Kajal Nandi, Binita Goswami","doi":"10.1515/dmpt-2024-0073","DOIUrl":"https://doi.org/10.1515/dmpt-2024-0073","url":null,"abstract":"<p><p>The review article, \"Navigating the Crossroads of Cell Death: Interplay and Intersections Among Ferroptosis, Apoptosis, and Autophagy,\" delves into the complex interactions between these three key cell death pathways. Understanding how ferroptosis, apoptosis, and autophagy intersect is crucial for maintaining cellular homeostasis. Each pathway represents a unique mechanism of cell death, and recent research highlights their intricate interconnections and mutual influences. Exploring these relationships is vital for comprehending how cells make fate decisions and how these processes are implicated in various diseases. The review's significance lies in elucidating the molecular details of cell death and providing insight into how cells balance survival and death. The interplay among ferroptosis, apoptosis, and autophagy has important implications for developing therapeutic interventions, particularly in diseases where cell death regulation is disrupted. By examining the molecular crosstalk between these pathways, researchers can identify new drug targets and devise strategies to modulate cell fate effectively. This review aims to enhance our understanding of cell biology by offering a detailed perspective on the dynamic and interconnected nature of these cell death mechanisms.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143991420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systems pharmacology of phytochemical anacardic acid in the chemoprevention of hepatocellular carcinoma.","authors":"Sangita Panda, Enketeswara Subudhi, Sweta Padma Routray, Sujit Nair","doi":"10.1515/dmpt-2024-0099","DOIUrl":"https://doi.org/10.1515/dmpt-2024-0099","url":null,"abstract":"<p><strong>Objectives: </strong>Hepatocellular carcinoma (HCC) is a common type of liver cancer that progresses quickly and has limited treatment options. Nutraceutical anacardic acid (AA), a bioactive compound derived from cashew nut shell, has emerged as a potential candidate for HCC treatment owing to its reported anti-inflammatory, anticancer and diverse pharmacological properties. In the present study, we investigate the potential of AA as an HCC inhibitor using molecular docking, gene ontology, and network pharmacology.</p><p><strong>Methods: </strong>The pharmacokinetic and physicochemical properties of AA were assessed using Swiss ADME. SuperPred, Similarity Ensemble Approach, ChEMBL and Swiss Target Prediction online tools were used for determining molecular targets of AA. In addition, GeneCards, NCBI, DisGeNET and UniProt ID were used to search the targets of HCC and the top 25 hub genes were determined using Cytohubba plugin. A protein protein interaction (PPI) network was constructed through the STRING database. Gene Ontology (GO) biological process and Kyoto Encyclopaedia of Genes and Genes (KEGG) pathway enrichment analysis were performed through FunRich and ShinyGO 0.77. Moreover, molecular docking studies were performed on NF-κB and GSK-3β. The expression levels of the hub genes were also validated by western blotting.</p><p><strong>Results: </strong>Comprehensive data analysis identified 375 targets for AA and 11,333 for HCC, with 264 targets in common. Network analysis determined 25 key HCC targets, including caspase-3, and NF-κB. Gene ontology and topology analysis highlighted essential pathways implicated in HCC progression such as the renin-angiotensin system, VEGF signalling, and apoptosis. Molecular docking analysis revealed strong binding affinity of HCC proteins with NF-κB and GSK-3β. Upregulation of p-NRF2 and p-GSK-3β, and downregulation of p-NF-κB and caspase-1 expression were validated using western blotting.</p><p><strong>Conclusions: </strong>Taken together, our study highlights the potential of AA as a promising chemopreventive agent for HCC because of its significant modulatory effects on important regulatory proteins linked to cell division, inflammation, apoptosis, and antioxidant response.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143986903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute and sub-chronic oral GLP toxicity of Withania somnifera root extract in Sprague Dawley rats.","authors":"Pralhad Wangikar, Pradhnya Chaudhari, Eshita Sharma, Chhaya Godse, Ashit Vora, Sujit Nair","doi":"10.1515/dmpt-2024-0100","DOIUrl":"https://doi.org/10.1515/dmpt-2024-0100","url":null,"abstract":"","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143976686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic variants in <i>NUDT15</i> gene their clinical implications in cancer therapy.","authors":"Yazun Jarrar, Maria Ghishan, Fatima Khirfan, Nancy Hakooz","doi":"10.1515/dmpt-2025-0003","DOIUrl":"https://doi.org/10.1515/dmpt-2025-0003","url":null,"abstract":"<p><p>Individual variations in the response to thiopurine-based anticancer drugs are influenced by genetic and environmental factors, making it challenging to optimize dosing and minimize toxicity. Among the key genes involved, genetic variations in the <i>nudix hydrolase 15</i> (<i>NUDT15</i>) gene affect on thiopurine metabolism, thus influencing drug efficacy and the risk of severe adverse effects, such as myelosuppression, These variations also contribute to inter-individual differences in drug tolerance and clinical outcomes. Despite the recognized impact of <i>NUDT15</i> variations, there has been limited comprehensive exploration of these variants and their clinical significance in thiopurine therapy. This review provides a thorough analysis of <i>NUDT15</i> genetic variants by synthesizing findings from prior clinical studies and employing <i>in silico</i> analyses to predict the functional effects of variants with uncertain significance. Comprehensive analysis of <i>NUDT15</i> variants and their interactions with other metabolic pathways could offer valuable insights for advancing personalized medicine in cancer treatment. This review aims to establish a foundation for integrating <i>NUDT15</i> genetic information into the clinical practice, reducing toxicity, and improved therapeutic outcomes in patients undergoing thiopurine-based chemotherapy.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143989486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the add on effect of <i>Majoone Sarkhas</i> with levothyroxine in primary hypothyroidism: a randomized standard control adjuvant clinical study.","authors":"Md Anzar Alam, Mohd Aleemuddin Quamri, Ghulamuddin Sofi, Nafis Haider","doi":"10.1515/dmpt-2024-0096","DOIUrl":"https://doi.org/10.1515/dmpt-2024-0096","url":null,"abstract":"<p><strong>Objectives: </strong>Primary hypothyroidism is a prevalent endocrine disorder, typically treated with levothyroxine (LT). However, prolonged use of LT may result in complications and suboptimal outcomes for some patients. <i>Majoone Sarkhas</i> (MS), is a polyherbal formulation comprises four plants: <i>Commiphora mukul</i>, <i>Operculina turpethum</i>, <i>Embelia tseriam-cottam</i>, and <i>Dryopteris filix-mas</i>. It is traditionally used in Unani medicine for managing hypothyroidism associated conditions. The aim of this study was to assess the synergistic effect of <i>Majoone Sarkhas</i> in combination with LT for the treatment of primary hypothyroidism.</p><p><strong>Methods: </strong>This randomized, single blind, standard clinical trial involved 100 subjects allocated into two groups: an adjuvant treatment group (n=50) and a standard control group (n=50). The adjuvant group received 10 g of MS twice daily in addition LT once daily, while the control group was treated with LT alone once daily. Both groups underwent treatment for 60 days. Changes in thyroid-stimulating hormone (TSH), free tri-iodothyronine (FT3), and free-thyroxine (FT4) levels from baseline to the 60th day were recorded and analyzed statistically to evaluate the outcomes.</p><p><strong>Results: </strong>The study showed adjuvant group (MS + LT) had more reduction (4.99 vs. 3.93) in serum TSH level in comparison to control group (LT), which was statistically significant (p<0.001), it also showed increase in serum FT3 (2.88 ± 0.31 vs. 2.97 ± 0.44) and FT4 (1.06 ± 0.17 vs. 1.20 ± 0.27) levels, when compared with baseline values and after completion of trial.</p><p><strong>Conclusions: </strong>The change in thyroid function profiles among adjuvant group, receiving MS with LT in primary hypothyroidism was both clinically and statistically significant. The safety parameters those were followed by serum level of ALT, AST, blood urea and serum creatinine were within the range, indicating the MS is safe medication to be used as an adjuvant therapy with LT (Clinical Trial Registration Code: CTRI/2018/02/011962).</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An open-label, single dose, safety and pharmacokinetic study of <i>Withania somnifera</i> root extract in healthy volunteers.","authors":"Eshita Sharma, Gayatri Ganu, Ketan Kshirsagar, Ashwin Shah, Umakant Mahale, Anirudh Mehta, Sujit Nair","doi":"10.1515/dmpt-2024-0089","DOIUrl":"10.1515/dmpt-2024-0089","url":null,"abstract":"<p><strong>Objectives: </strong><i>Withania somnifera</i> (WS), also known as Ashwagandha, is a health-beneficial Ayurvedic medicinal plant with great potential as an adaptogen with rejuvenating and anti-aging effects. However, studies investigating pharmacokinetics (PK), safety, and tolerability of WS on humans are limited. The present study evaluated PK, safety, and tolerability of WS root extract (2.5 % total withanolides) capsules upon oral administration of two capsules of 200 mg each (total 400 mg) in healthy male and female volunteers.</p><p><strong>Methods: </strong>An open label, single dose, clinical design comprising healthy volunteers was employed. The study evaluated PK parameters of the four bioactive constituents <i>viz.</i> withanoside IV, withaferin A, 12-deoxy-withastramonolide, and withanolide A in WS root extract after analysis of plasma using a validated UHPLC-MS/MS method. Further, safety and tolerability assessment for vital signs, testing for organ function, urine examination, X-ray, ECG, as well as adverse events profile were also investigated.</p><p><strong>Results: </strong>After oral administration of 2 WS capsules (200 mg each), the participants reported normal physical, hematological, and biochemical parameters with no abnormalities in safety metrics. For the four bioactives, the exposure parameters range between 0.472 and 4.468 ng/mL (C_max), 1.000-1.416 h (T_max), and 2.051-13.319 ng/mL*h (AUC 0-t). Further, t_1/2 (1.696-4.377 h), lambda_z (0.141-0.282 L/h), Cl/F (0.065-0.954 mg/(ng/ml)/h), AUMC 0-inf_obs (21.720-80.485 ng/mL*hˆ2) and MRT 0-inf_obs (3.680-7.516 h) also differed for each bioactive.</p><p><strong>Conclusions: </strong>The present study elucidated the PK of WS and showed that healthy male and female volunteers may safely consume WS capsules at a dose of 400 mg (2 capsules of 200 mg) without any harmful effects.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":"23-34"},"PeriodicalIF":0.0,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143440242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CYP2D6 genetic polymorphisms impact on tamsulosin efficacy and safety in patients with benign prostatic hyperplasia.","authors":"Shokhrukh Abdullaev, Maksim Shatokhin, Ivan Sychev, Aleksandr Krasnov, Pavel Bochkov, Svetlana Tuchkova, Oleg Teodorovich, Oleg Loran, Sherzod Abdullaev, Dmitry Sychev","doi":"10.1515/dmpt-2024-0061","DOIUrl":"10.1515/dmpt-2024-0061","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objectives: &lt;/strong&gt;The clinical outcomes of tamsulosin therapy for LUTS/BPH patients vary, with up to one-third of patients reporting unsatisfactory results. Enhancing the effectiveness and safety of tamsulosin therapy for LUTS/BPH patients remains a significant challenge in current medical practice. Limited data exists regarding the impact of CYP2D6 genetic polymorphisms on the efficacy and safety of tamsulosin therapy. Given that tamsulosin is metabolized by CYP2D6, variations in this enzyme may influence the drug's pharmacodynamic response. The objective of this study was to evaluate the impact of CYP2D6 pharmacogenetic markers on tamsulosin efficacy and safety in patients with LUTS associated with BPH.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;The study included 142 male patients with LUTS and a confirmed diagnosis of BPH (N40 ICD-10). Patients were followed for a minimum of 8 weeks and underwent four examinations (at days 0, 14, 28, and 56). Treatment efficacy was assessed using the IPSS with quality of life assessment, transrectal ultrasound of the prostate with estimation of prostate volume and residual urine volume, and maximum urinary flow rate (Qmax). Allelic variants of CYP2D6 (&lt;i&gt;*2, *3, *4, *6, *9, *10&lt;/i&gt;, and &lt;i&gt;*41&lt;/i&gt;) were determined by polymerase chain reaction in all patients..&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;In the subgroup with moderate symptoms, individuals classified as poor and intermediate metabolizers exhibited significantly higher ΔQmax compared to normal metabolizers (4.25 [2.5; 6.1] vs. [0.6; 4.3], p=0.001826). Moreover, carriers of the &lt;i&gt;CYP2D6*10&lt;/i&gt; CT heterozygous genotype demonstrated lower IPSS scores at the last two visits compared to those with the CC genotype (visit 3: -7.45 ± 3.93 vs. -5.25 ± p=0.05; visit 4: -8.91 ± 3.88 vs. -6.31 ± 5.7), as well as reduced IPSS irritative symptoms at visit 2 (-3.87 ± 2.70 vs -2.47 ± 3.1, p=0.05), and a significant increase in ΔQmax ([2.5; 5.9] vs. [0.6; 4.7], p=0.01). In the subgroup with severe symptoms, individuals with &lt;i&gt;CYP2D6*41&lt;/i&gt; GA + AA genotypes exhibited less residual urine volume following therapy compared to those with the GG genotype ([15.0; 32.0] vs. [3.0; 19.0], p=0.007029). The CYP2D6 polymorphic variants did not impact the tamsulosin safety. The study did not reach the estimated power for &lt;i&gt;CYP2D6*3&lt;/i&gt;, &lt;i&gt;CYP2D6*6&lt;/i&gt;, and &lt;i&gt;CYP2D6*9&lt;/i&gt; polymorphisms due to their low frequency of occurrence in the study population. The multivariate logistic regression model indicated that potential predictors of tamsulosin therapy efficacy in LUTS/BPH patients may include BMI (p&lt;0.001), prostate volume (p&lt;0.002), as well as the carriage of &lt;i&gt;CYP2D6*4&lt;/i&gt; (p&lt;0.001) and &lt;i&gt;CYP2D6*10&lt;/i&gt; (p=0.012) markers. The model explained 81.9 % of the variance in the predicted outcome and accurately forecasted tamsulosin therapy efficacy in BPH with a precision of 92.1 %.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;The present study identified potential markers that could serve as p","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":"55-67"},"PeriodicalIF":0.0,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143406285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting of factors associated with valsartan response among hypertensive patients attending the Jordan University Hospital.","authors":"Shahd Khalil, Aseel Quran, Leen Thalji, Malk Al-Adamat, Lina Sabha, Joud Khraisat, Abdel Rahman Al Na'ami, Hatem Al-Jazzazi, Hussein Alhawari, Yazun Jarrar","doi":"10.1515/dmpt-2024-0088","DOIUrl":"10.1515/dmpt-2024-0088","url":null,"abstract":"<p><strong>Objectives: </strong>There is an inter-individual in the valsartan response among hypertensive patients. However, clinical factors associated with this variation in the response is still not fully understood. The major purpose of this study is to predict the factors associated with valsartan response and their influence on decreasing blood pressure among patients.</p><p><strong>Methods: </strong>This study is a cross-sectional observational study. It included 91 hypertensive patients on valsartan treatment, selected through simple random sampling from the Jordan University Hospital. The clinical data was collected through documented medical records in the hospital's computerized system. The data was analyzed using the chi-square test to compare frequencies and categories.</p><p><strong>Results: </strong>Patients were divided into systolic and diastolic responders. No statistical significance was found between systolic response to valsartan's and gender, smoking, age, BMI, lipid profile and HbA_1c status. Diastolic responders had a positive significance of p-value = 0.006 with BMI categories, however there was no significance with any other factor.</p><p><strong>Conclusions: </strong>There was a better diastolic response to valsartan among hypertensive patients with lower BMI levels. BMI can be considered as a factor to personalize the therapy among patients on valsartan. However, further clinical studies with larger sample size are needed to confirm these data.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":"69-75"},"PeriodicalIF":0.0,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143254955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}